2. Signaling Pathways
  3. GPCR/G Protein
  4. Bombesin Receptor
  5. Bombesin Receptor Agonist

Bombesin Receptor Agonist

Bombesin Receptor Agonists (8):

Cat. No. Product Name Effect Purity
  • HY-14342
    MK-5046
    		Agonist 99.67%
    MK-5046 is a potent, selective and orally active Bombesin receptor subtype-3 (BRS-3) allosteric agonist with an IC50 and an EC50 value of 27 and 25 nM for hBRS-3, respectively. MK-5046 inhibits food intake and reduces body weight of diet-induced obese (DIO) mouse models. MK-5046 can be used for the research of obesity.
  • HY-103281
    Litorin
    		Agonist 99.51%
    Litorin, an amphibian bombesin peptide derivative, is an bombesin receptor agonist. Litorin stimulates the contraction of smooth muscle, stimulates gastrin, gastric acid, and pancreatic secretion, and suppresses the nutriment in vivo.
  • HY-P1423A
    BA 1 TFA
    		Agonist 99.76%
    BA 1 TFA is a potent agonist for the bombesin (BB) family of receptors. BA1 binds with high affinity to Bombesin receptor subtype-3 (BRS3), gastrin releasing peptide receptor (GRPR), neuromedin B receptor (NMBR) with IC50s of 6, 0.4, 2.5 nM.
  • HY-W343750
    [Tyr4]-Bombesin
    		Agonist
    [Tyr4]-Bombesin is a Bombesin analogue, is a ligand of gastrin-releasing peptide receptor (GRPR).
  • HY-W681071
    BRS-3 receptor agonist-2
    		Agonist
    BRS-3 receptor agonist-2 (compound 2) is a potent BRS-3 receptor agonist, with an EC50 of 2.5 nM for mouse BRS-3 receptor.
  • HY-P1423
    BA 1
    		Agonist
    BA 1 is a potent agonist for the bombesin (BB) family of receptors. BA 1 binds with high affinity to Bombesin receptor subtype-3 (BRS3), gastrin releasing peptide receptor (GRPR), neuromedin B receptor (NMBR) with IC50s of 6, 0.4, 2.5 nM.
  • HY-P5072
    GRP (14-27) (human, porcine, canine)
    		Agonist
    GRP (14-27) (human, porcine, canine) is a bombesin receptor ligand. The specific binding of GRP (14-27) is inhibited by GTP and GDP, whereas GMP was without effect.
  • HY-154985
    DSO-5a
    		Agonist
    DSO-5a is a potent, selective, orally active BB3 agonist. DSO-5a is a representative DMAKO-00 derivative compound. DSO-5a upregulates ppar-γ activity through BB3 and activates ERK1/2 phosphorylation. DSO-5a can be used in diabetes-related research.